192 related articles for article (PubMed ID: 8100562)
1. Enhancement of reversing effect of cyclosporin A on vincristine resistance by anti-P-glycoprotein monoclonal antibody MRK-16.
Naito M; Tsuge H; Kuroko C; Tomida A; Tsuruo T
Jpn J Cancer Res; 1993 May; 84(5):489-92. PubMed ID: 8100562
[TBL] [Abstract][Full Text] [Related]
2. [Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16, and their synergistic modulation of multidrug resistance].
Naito M; Tsuruo T
Gan To Kagaku Ryoho; 1994 Feb; 21(3):395-402. PubMed ID: 7906507
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance.
Naito M; Tsuge H; Kuroko C; Koyama T; Tomida A; Tatsuta T; Heike Y; Tsuruo T
J Natl Cancer Inst; 1993 Feb; 85(4):311-6. PubMed ID: 7678867
[TBL] [Abstract][Full Text] [Related]
4. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody.
Pearson JW; Fogler WE; Volker K; Usui N; Goldenberg SK; Gruys E; Riggs CW; Komschlies K; Wiltrout RH; Tsuruo T
J Natl Cancer Inst; 1991 Oct; 83(19):1386-91. PubMed ID: 1681110
[TBL] [Abstract][Full Text] [Related]
5. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
Fogler WE; Pearson JW; Volker K; Ariyoshi K; Watabe H; Riggs CW; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1995 Jan; 87(2):94-104. PubMed ID: 7707396
[TBL] [Abstract][Full Text] [Related]
6. Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies.
Watanabe T; Naito M; Kokubu N; Tsuruo T
J Natl Cancer Inst; 1997 Apr; 89(7):512-8. PubMed ID: 9086008
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes.
Yano S; Sone S; Nishioka Y; Naito M; Tsuruo T; Ogura T
Jpn J Cancer Res; 1994 Feb; 85(2):194-203. PubMed ID: 7511575
[TBL] [Abstract][Full Text] [Related]
8. Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein.
Broxterman HJ; Kuiper CM; Schuurhuis GJ; Tsuruo T; Pinedo HM; Lankelma J
Biochem Pharmacol; 1988 Jun; 37(12):2389-93. PubMed ID: 2898943
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of the reversal activity of SDZ PSC833 on multi-drug resistance by an anti-P-glycoprotein monoclonal antibody MRK-16.
Naito M; Watanabe T; Tsuge H; Koyama T; Oh-hara T; Tsuruo T
Int J Cancer; 1996 Jul; 67(3):435-40. PubMed ID: 8707421
[TBL] [Abstract][Full Text] [Related]
10. Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein.
Matsuo H; Wakasugi M; Takanaga H; Ohtani H; Naito M; Tsuruo T; Sawada Y
J Control Release; 2001 Nov; 77(1-2):77-86. PubMed ID: 11689261
[TBL] [Abstract][Full Text] [Related]
11. Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein.
Tsuji A; Tamai I; Sakata A; Tenda Y; Terasaki T
Biochem Pharmacol; 1993 Sep; 46(6):1096-9. PubMed ID: 8105783
[TBL] [Abstract][Full Text] [Related]
12. Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA.
Dietel M; Herzig I; Reymann A; Brandt I; Schaefer B; Bunge A; Heidebrecht HJ; Seidel A
J Cancer Res Clin Oncol; 1994; 120(5):263-71. PubMed ID: 7907333
[TBL] [Abstract][Full Text] [Related]
13. Derivation and characterisation of a mouse tumour cell line with acquired resistance to cyclosporin A.
Wright KA; Twentyman PR
Eur J Cancer; 1993; 29A(3):389-94. PubMed ID: 8104444
[TBL] [Abstract][Full Text] [Related]
14. Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein.
Botling J; Liminga G; Larsson R; Nygren P; Nilsson K
Int J Cancer; 1994 Jul; 58(2):269-74. PubMed ID: 7913083
[TBL] [Abstract][Full Text] [Related]
15. Elimination of drug-resistant myeloma tumor cell lines by monoclonal anti-P-glycoprotein antibody and rabbit complement.
Kulkarni SS; Wang ZM; Spitzer G; Taha M; Hamada H; Tsuruo T; Dicke KA
Blood; 1989 Nov; 74(6):2244-51. PubMed ID: 2572283
[TBL] [Abstract][Full Text] [Related]
16. Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance.
Sparrow RL; Hall FJ; Siregar H; Van der Weyden MB
Leuk Res; 1993 Nov; 17(11):941-7. PubMed ID: 7901453
[TBL] [Abstract][Full Text] [Related]
17. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma.
Pilarski LM; Belch AR
Blood; 1994 Feb; 83(3):724-36. PubMed ID: 7507731
[TBL] [Abstract][Full Text] [Related]
18. Functionally active homodimer of P-glycoprotein in multidrug-resistant tumor cells.
Naito M; Tsuruo T
Biochem Biophys Res Commun; 1992 May; 185(1):284-90. PubMed ID: 1350903
[TBL] [Abstract][Full Text] [Related]
19. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.
van der Graaf WT; de Vries EG; Timmer-Bosscha H; Meersma GJ; Mesander G; Vellenga E; Mulder NH
Cancer Res; 1994 Oct; 54(20):5368-73. PubMed ID: 7923167
[TBL] [Abstract][Full Text] [Related]
20. [Detection of multidrug resistant cells in human malignant diseases by monoclonal antibodies and strategy to eradicate resistant malignant cells].
Shimoyama M; Ohtsu T; Ishida Y; Shimada Y; Tobinai K; Minato K; Tsuruo T
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 2):611-6. PubMed ID: 2565103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
